News | October 12, 2021
Tarsons earmarks funds from IPO to double capacity at its Panchla facility
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The transaction is anticipated to close in the first quarter of 2022
The 462,000 square foot state-of-the-art building targeting LEED Zero certification and is designed to be the most sustainable commercial lab building in Cambridge
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Lifebit's accompanying suite of AI-powered end-to-end software solutions provide faster data insights, accelerate drug discovery pipelines, and improve clinical trials success
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Subscribe To Our Newsletter & Stay Updated
